India’s scientific future lies in moving from “paper-thin” academic metrics to “patient-ready” translational impact. By leveraging the ANRF to pioneer peroral nanomedicine, India can stop chasing global standards and start setting them.
The trajectory of India’s scientific growth is defined by a vibrant spirit of innovation and an urgent commitment to scaling impactful solutions. As the nation pursues its goal of becoming a global powerhouse, a clear opportunity exists to align academic excellence with socio-economic reality. By embracing a unified vision bolstered by the operationalisation of the Anusandhan National Research Foundation (ANRF), India is successfully pivoting toward a structure that prioritises domestic needs and high-impact translation through strategic collaboration.
India’s real scientific challenge is not discovery, its translation
India’s unique competitive edge lies in its unparalleled ability to scale affordable, high-quality medicine. While high-tech biologicals continue to advance, peroral dosage forms remain the industry’s cornerstone, representing the most accessible bridge to healthcare for a massive global population. By focusing research specifically on peroral nanomedicine, overcoming physiological barriers like gastric pH degradation and mucosal permeation, and leveraging R&D reinvestments from industry leaders, India can transform “chronic disease management” into a self-sustaining export engine. This evolution involves developing “novel functional excipients”, converting complex injectables into patient-friendly oral formats, and serving as a specialised Contract Development and Manufacturing Organizations (CDMOs) to minimise drug attrition through advanced nanoparticle formulation (nanomedicines).
India is uniquely positioned to lead the global transition in making nanomedicines, traditionally reserved for intravenous routes, viable for peroral administration, setting a new international standard for patient care. To date, global regulatory frameworks have almost exclusively addressed intravenous targeted nanomedicines, leading to a prevailing industry presumption that nanotechnology is synonymous with intravenous delivery. India has the opportunity to disrupt this status quo by providing a definitive regulatory direction, including drafting the world’s first comprehensive guidelines for peroral nanomedicine. By establishing this framework, India does not just follow international standards; it creates them.
From bench to market: Why India needs patient capital, not fast papers
This immense potential remains largely theoretical because the path from “bench to bedside” is currently blocked by a dual crisis of capital and culture. While deep-tech startups recognise these opportunities, they are frequently caught off-guard by the “exit-strategy obsession” of traditional venture capital. To overcome this, funding agencies must look beyond blue-sky innovation and incentivize the “unsexy” stages of development-such as pilot scaling, and rigorous preclinical, and early clinical validation, which currently fall outside the remit of academic grants. This structural misalignment between short-term capital expectations and the long-term gestation periods of nanotechnological breakthroughs often stifles innovation in its infancy, leaving brilliant translational work stranded in a “valley of death”. To bridge this gap, India must pivot toward “patient capital” and strategic sovereign funding, ensuring that deep-tech ventures are nurtured by investors who value long-term sovereignty over immediate liquidity.
Institutional reform: Beyond the “rolling advertisement” culture
Capital alone cannot bridge the valley if the institutional framework remains stagnant. The persistence of “rolling advertisements” across NIPERs, IITs, IISERs, and INST has evolved from a recruitment strategy into a symptom of a deeper structural crisis. While these open-ended calls suggest a constant search for talent, they effectively mask a rigid institutional culture that over-indexes on traditional academic metrics like h‑index and publication counts at the expense of translational expertise. This has created a bottleneck that alienates high-caliber, mid-career professionals. The “rolling” status is no longer a sign of growth, but an admission of an inability to integrate seasoned, market-aware experts into a traditional, hierarchical framework.
The ILF model: Fueling the lab-to-market pipeline
The solution lies in a structural shift where the State provides the foundational platform, but Industry provides the operational fuel through an Industry-Linked Faculty (ILF) model. Proposed here as a high-impact pilot program under the mandate of the ANRF, this 100% industry-funded track targets expert-tier professionals in translational research. Under a 60⁄40 functional split, these experts dedicate 60% of their bandwidth to solving high-stakes industrial challenges, such as the complex transition of nanomedicines from lab to market, while the remaining 40% is reserved for the rigorous teaching and mentorship required to build a world-class, industry-ready workforce.
To ensure this model is commercially viable, it must be underpinned by a modern, industry-weighted intellectual property (IP) framework. In this shared IP ecosystem, the sponsoring industry partner retains a majority share, typically 70% to 80%, ensuring the commercial freedom and “right to play” necessary for massive capital reinvestment. The host academic institution retains a minority stake and a royalty-linked revenue stream, ensuring the lab remains self-sustaining while providing the financial basis to align faculty incentives with industrial outcomes. This model serves both Industry and Government with precision: industry gains direct access to state-of-the-art infrastructure and elite talent, while the Government fulfills its mandate to scale high-quality education without additional fiscal overhead.
Asserting global authority
In this framework, the “return to India” movement transcends philanthropy to become a self-sustaining economic engine. By focusing on national bottlenecks through collaborative innovation, India’s elite institutes move beyond traditional academic metrics to become the primary drivers of a resilient mission that delivers genuine, life-changing impact on a global scale.
Whilst basic science remains the indispensable underpinning of our research, the future necessitates more than mere discovery; it demands a decisive intervention in the high-stakes arena of translational drug delivery. By bridging this gap with precision, India will move beyond the mere adoption of global benchmarks, and instead, assert the authority to define them.